Cargando…

Immunosuppressive therapy in children with primary nephrotic syndrome: single center experience, Karachi, Pakistan

BACKGROUND: Majority of children with nephrotic syndrome are steroid sensitive, but treatment of difficult to treat nephrotic (frequent relapsing, steroid dependent and steroid resistant) syndrome is challenging. Low dose steroid, levamisole, cyclophosphamide (CPM), mycophenolate mofetil (MMF) and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Moorani, Khemchand Netaram, Hotchandani, Harnam Moolchand, Zubair, Aasia Mohammad, Lohana, Neelesh Chander, Veerwani, Nanga Ram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607530/
https://www.ncbi.nlm.nih.gov/pubmed/31269922
http://dx.doi.org/10.1186/s12882-019-1347-5
_version_ 1783432112646389760
author Moorani, Khemchand Netaram
Hotchandani, Harnam Moolchand
Zubair, Aasia Mohammad
Lohana, Neelesh Chander
Veerwani, Nanga Ram
author_facet Moorani, Khemchand Netaram
Hotchandani, Harnam Moolchand
Zubair, Aasia Mohammad
Lohana, Neelesh Chander
Veerwani, Nanga Ram
author_sort Moorani, Khemchand Netaram
collection PubMed
description BACKGROUND: Majority of children with nephrotic syndrome are steroid sensitive, but treatment of difficult to treat nephrotic (frequent relapsing, steroid dependent and steroid resistant) syndrome is challenging. Low dose steroid, levamisole, cyclophosphamide (CPM), mycophenolate mofetil (MMF) and calcineurin inhibitors (CNIs) are the common options of treatment. Objective of the study was to determine the response to steroid and alternative immunosuppressive agents (ISAs) in children with difficult nephrotic syndrome (DNS). METHODS: This is a retrospective cohort study of 176 children with DNS, managed over 12 years at The Kidney Center-Postgraduate Training Institute, Karachi- Pakistan from 2005 to 2017. Initial episode was treated with daily oral prednisolone (OP) for 4–8 weeks followed by alternate day OP for 12–24 weeks. Subsequently low dose OP, levamisole (Leva)and cyclophosphamide was used for frequent relapsing (FR)/ steroid dependent (SD). All with initial steroid resistance and non- responders to leva and or cyclophosphamide were biopsied and treated with CNIs and MMF. Data was analyzed using descriptive statistics. RESULTS: There were 130(73.86%) children with FR/SD and 46(26.13%) with SRNS. All children with SR (46) and 86 with FR/SD were biopsied. Minimal change disease (60.60%) and focal segmental glomerulosclerosis (FSGS 23%) were the two common lesions. Majority (73.86%) received single OP whereas divided doses were administered in 26.13% cases. Daily OP was used for 4, 6 and 8 weeks in 61.36,28.4 and10.22% respectively. Steroids were tapered over 3 (31.81%),4 (52.27%) and 6 months (15.90%). Levamisole, CPM, cyclosporin (CS) and MMF were used sequentially in 45, 54.23, 50 and 20% respectively. Combination of MMF and CS was used in 11.29% of cases. Levamisole was effective in 80%, CPM induced complete remission (CR, 57.77%) or partial remission (PR, 22.22%), CS induced CR 46.59% and PR 39.77%. MMF showed PR and CR 69 and 12.82% respectively. At last follow up, 46% were maintaining remission while off treatment, whereas 35% are maintaining remission on therapy,10.23% lost- to-follow, 5.68% progressed to chronic kidney disease. Mortality was 2.84% and it was due to infection and uremia. CONCLUSION: Majority had steroid sensitive MCD. Levamisole and cyclophosphamide were effective in maintaining remission in FR/ SD. FSGS was responsible for resistance to steroid and alternative ISAs. Cyclosporin was effective in inducing remission in SRNS. Mortality was less than 3%.
format Online
Article
Text
id pubmed-6607530
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66075302019-07-12 Immunosuppressive therapy in children with primary nephrotic syndrome: single center experience, Karachi, Pakistan Moorani, Khemchand Netaram Hotchandani, Harnam Moolchand Zubair, Aasia Mohammad Lohana, Neelesh Chander Veerwani, Nanga Ram BMC Nephrol Research Article BACKGROUND: Majority of children with nephrotic syndrome are steroid sensitive, but treatment of difficult to treat nephrotic (frequent relapsing, steroid dependent and steroid resistant) syndrome is challenging. Low dose steroid, levamisole, cyclophosphamide (CPM), mycophenolate mofetil (MMF) and calcineurin inhibitors (CNIs) are the common options of treatment. Objective of the study was to determine the response to steroid and alternative immunosuppressive agents (ISAs) in children with difficult nephrotic syndrome (DNS). METHODS: This is a retrospective cohort study of 176 children with DNS, managed over 12 years at The Kidney Center-Postgraduate Training Institute, Karachi- Pakistan from 2005 to 2017. Initial episode was treated with daily oral prednisolone (OP) for 4–8 weeks followed by alternate day OP for 12–24 weeks. Subsequently low dose OP, levamisole (Leva)and cyclophosphamide was used for frequent relapsing (FR)/ steroid dependent (SD). All with initial steroid resistance and non- responders to leva and or cyclophosphamide were biopsied and treated with CNIs and MMF. Data was analyzed using descriptive statistics. RESULTS: There were 130(73.86%) children with FR/SD and 46(26.13%) with SRNS. All children with SR (46) and 86 with FR/SD were biopsied. Minimal change disease (60.60%) and focal segmental glomerulosclerosis (FSGS 23%) were the two common lesions. Majority (73.86%) received single OP whereas divided doses were administered in 26.13% cases. Daily OP was used for 4, 6 and 8 weeks in 61.36,28.4 and10.22% respectively. Steroids were tapered over 3 (31.81%),4 (52.27%) and 6 months (15.90%). Levamisole, CPM, cyclosporin (CS) and MMF were used sequentially in 45, 54.23, 50 and 20% respectively. Combination of MMF and CS was used in 11.29% of cases. Levamisole was effective in 80%, CPM induced complete remission (CR, 57.77%) or partial remission (PR, 22.22%), CS induced CR 46.59% and PR 39.77%. MMF showed PR and CR 69 and 12.82% respectively. At last follow up, 46% were maintaining remission while off treatment, whereas 35% are maintaining remission on therapy,10.23% lost- to-follow, 5.68% progressed to chronic kidney disease. Mortality was 2.84% and it was due to infection and uremia. CONCLUSION: Majority had steroid sensitive MCD. Levamisole and cyclophosphamide were effective in maintaining remission in FR/ SD. FSGS was responsible for resistance to steroid and alternative ISAs. Cyclosporin was effective in inducing remission in SRNS. Mortality was less than 3%. BioMed Central 2019-07-03 /pmc/articles/PMC6607530/ /pubmed/31269922 http://dx.doi.org/10.1186/s12882-019-1347-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Moorani, Khemchand Netaram
Hotchandani, Harnam Moolchand
Zubair, Aasia Mohammad
Lohana, Neelesh Chander
Veerwani, Nanga Ram
Immunosuppressive therapy in children with primary nephrotic syndrome: single center experience, Karachi, Pakistan
title Immunosuppressive therapy in children with primary nephrotic syndrome: single center experience, Karachi, Pakistan
title_full Immunosuppressive therapy in children with primary nephrotic syndrome: single center experience, Karachi, Pakistan
title_fullStr Immunosuppressive therapy in children with primary nephrotic syndrome: single center experience, Karachi, Pakistan
title_full_unstemmed Immunosuppressive therapy in children with primary nephrotic syndrome: single center experience, Karachi, Pakistan
title_short Immunosuppressive therapy in children with primary nephrotic syndrome: single center experience, Karachi, Pakistan
title_sort immunosuppressive therapy in children with primary nephrotic syndrome: single center experience, karachi, pakistan
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607530/
https://www.ncbi.nlm.nih.gov/pubmed/31269922
http://dx.doi.org/10.1186/s12882-019-1347-5
work_keys_str_mv AT mooranikhemchandnetaram immunosuppressivetherapyinchildrenwithprimarynephroticsyndromesinglecenterexperiencekarachipakistan
AT hotchandaniharnammoolchand immunosuppressivetherapyinchildrenwithprimarynephroticsyndromesinglecenterexperiencekarachipakistan
AT zubairaasiamohammad immunosuppressivetherapyinchildrenwithprimarynephroticsyndromesinglecenterexperiencekarachipakistan
AT lohananeeleshchander immunosuppressivetherapyinchildrenwithprimarynephroticsyndromesinglecenterexperiencekarachipakistan
AT veerwaninangaram immunosuppressivetherapyinchildrenwithprimarynephroticsyndromesinglecenterexperiencekarachipakistan